Last reviewed · How we verify
Regular insulin added to TPN bag
Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition.
Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition. Used for Hyperglycemia management in patients receiving total parenteral nutrition (TPN), Blood glucose control in critically ill patients on parenteral nutrition support.
At a glance
| Generic name | Regular insulin added to TPN bag |
|---|---|
| Also known as | ATC code A10AB01, Actrapid® |
| Sponsor | Fundación Pública Andaluza Progreso y Salud |
| Drug class | Insulin (short-acting) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Metabolic |
| Phase | FDA-approved |
Mechanism of action
When added to TPN bags, regular insulin acts on insulin receptors to enhance glucose utilization by peripheral tissues and suppress hepatic glucose production. This prevents hyperglycemia that commonly occurs during parenteral nutrition, particularly in critically ill or stressed patients, and supports protein synthesis and metabolic stability.
Approved indications
- Hyperglycemia management in patients receiving total parenteral nutrition (TPN)
- Blood glucose control in critically ill patients on parenteral nutrition support
Common side effects
- Hypoglycemia
- Hypokalemia
- Lipodystrophy at injection sites
Key clinical trials
- Insulin in Total Parenteral Nutrition (PHASE4)
- Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: